Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
55,858,330
-
Share change
-
-265,230
-
Total reported value
-
$4,486,624,929
-
Put/Call ratio
-
96%
-
Price per share
-
$80.38
-
Number of holders
-
303
-
Value change
-
-$21,003,128
-
Number of buys
-
146
-
Number of sells
-
166
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2024
As of 30 Sep 2024,
HAEMONETICS CORP - Common Stock (HAE) was held by
303 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,858,330 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Capital Research Global Investors, WELLINGTON MANAGEMENT GROUP LLP, NEUBERGER BERMAN GROUP LLC, T. Rowe Price Investment Management, Inc., STATE STREET CORP, ROYCE & ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, and Thrivent Financial for Lutherans.
This page lists
303
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.